RSS
PhoreMost
Collaborative agreement signed for identification of novel drug targets
PhoreMost, UK-based biopharmaceutical company, has signed a collaborative agreement with Plexxikon, the small molecule structure-guided R&D centre of Daiichi Sankyo, for the identification of novel drug targets. more
Fund manager invests in spin out immune-oncology company NeoPhore
UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. more
The undruggables: Collaboration aims to uncover new therapies for neurodegenerative disorders
Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. more
PhoreMost awarded £1.4M Innovate UK funding to develop lead oncology programme
PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers. more
